Three Candidates In Running To Become FDA Commissioner, Including Acting Chief Ned Sharpless

The Trump administration is seriously considering three candidates to become US Food and Drug Administration commissioner when the legally mandated 210-day term of acting commissioner Norman “Ned” Sharpless ends on 4 November.

candidates in the running to become permanent FDA commissioner when the acting commissioner’s term ends Nov. 4
• Source: M.D. Anderson Cancer Center (Hahn photo); Harvard University Medical Faculty (Kimball photo); file photo (Sharpless photo)

While four former FDA commissioners on 3 September endorsed Ned Sharpless, the agency’s acting commissioner, to be the Trump administration’s permanent choice to lead the agency, an M.D. Anderson Cancer Center oncologist or Harvard University dermatologist may also be chosen.

Besides Sharpless, the other two candidates being considered to lead FDA are Harvard University dermatology professor Alexa Boer Kimball and...

More from Leadership

More from Medtech Insight

Expert Panels Remain Tough On Manufacturers And Their Notified Bodies

 

The EU’s extra layer of checks on clinical evidence is proving a difficult, and sometimes humiliating process, for many device companies whose products have come under the spotlight.

Rising Oncology Start-ups Recognized For Breakthrough Cancer Research

 

The Cancer Research Horizons Innovation Awards took place on July 10. Medtech Insight spoke to nominees for the women’s entrepreneur of the year award: Mireia Crispin-Ortuzar, CEO of 52 North Health; Anita Grigoriadis, CEO of PharosAI; and Maria Giovanna Lizio, Founder of WILD-Imaging Technology.

HeartFlow Takes Another Crack At Public Markets With $100M IPO Filing

 
• By 

AI heart imaging company HeartFlow filed for a $100m IPO after scrapping its 2022 SPAC plans. It remains unprofitable but is betting on FDA clearances, Medicare coverage and a demand for AI-powered diagnostics to win over investors.